MedPath

Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure

Phase 3
Conditions
Lung Neoplasms
Registration Number
NCT01687647
Lead Sponsor
University Hospital, Caen
Brief Summary

Workers exposed to asbestos are at high risk of lung cancer. Medical follow-up of this population relies on repeated CT-scans which are more accurate for detection of peripheral lesions, and expose to X-rays and to risk of false-positives. Analysis of sputum using automate cytometry may be of interest in this population, alone or in combination with CT-scan.

An ancillary study will evaluate the interest of blood predictive biomarkers.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • High professional asbestos exposure
  • Member of a former cohort recruited between 2000 and 2006 in Caen, Rouen and Le Havre (inclusion criteria: 50-75 years at the time of initial recruitment, high intermittent asbestos exposure >= 1 year, or high discontinuous asbestos exposure >=10 years). All the living members of the cohort will be contacted: a maximum of 1000 subjects is expected, probably less.
  • Informed consent signed
Exclusion Criteria
  • Personal history of lung cancer
  • Refusal of the study protocol
  • Uncontrolled asthma or lung failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Risk of false positivewithin 3 months

Ratio of false positives (RFP) for detection of lung cancer in reference to conventional cytology analysis of sputum

detection of lung cancerwithin 3 months

Ratio of sensitivities for detection of lung cancer in reference to conventionnal cytology analysis of sputum

Secondary Outcome Measures
NameTimeMethod
Sensitivity for lung cancer detection compared with CT-scanwithin 3 months

Ratio of sensitivity (RSN) for lung cancer detection in reference with CT scan.

Interest of the combination "cytometry + CT-scan" compared with CT-scan alone will also be evaluated.

Specificity for detection of lung cancerwithin 3 months

Ratio of false positives (RFP) of automated cytometry analysis compared with CT-scan screening.

The combination "automated cytometry + CTscan" will also be evaluated compared with CT scan alone.

Predictive BiomarkersAnnually during a maximum of 5 years

Frequency of specific biomarkers at the time of screening. Links between lung cancer during 5 years of prospective follow-up.

Trial Locations

Locations (3)

Caen University Hospital

🇫🇷

Caen, France

Le Havre Hospital

🇫🇷

Le Havre, France

Rouen University Hospital

🇫🇷

Rouen, France

Caen University Hospital
🇫🇷Caen, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.